Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tofacitinib Citrate

FDA-approved product (tablet, oral), marketed as Tofacitinib Citrate, Xeljanz, Xeljanz Xr.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tofacitinib Citrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psoriatic arthritis
  • Rheumatoid arthritis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Janus-associated kinase (jak) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tofacitinib Citrate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tofacitinib Citrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Tofacitinib in Recurrent GBM Patients

    NCT05326464 · start 2022-10-07

    Registered record
    Registry ID
    NCT05326464
    Conditions
    Glioblastoma
    Interventions
    Tofacitinib 10mg; Temozolomide; Lomustine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2022-10-07
    Completion
    2025-10-31
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma
    InterventionTofacitinib 10mg; Temozolomide; Lomustine
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory Complications

    NCT05104723 · start 2022-08-12

    Registered record
    Registry ID
    NCT05104723
    Conditions
    Chronic Granulomatous Disease; Inflammatory Gastrointestinal Disease; Inflammatory Skin Disease; Inflammatory Lung Disease
    Interventions
    XELJANZ (tofacitinib)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2022-08-12
    Completion
    2026-05-04
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Granulomatous Disease; Inflammatory Gastrointestinal Disease; Inflammatory Skin Disease; Inflammatory Lung Disease
    InterventionXELJANZ (tofacitinib)
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis

    NCT05133297 · start 2022-02-16

    Registered record
    Registry ID
    NCT05133297
    Conditions
    Rheumatoid Arthritis
    Interventions
    TLL-018; TLL-018; TLL-018; Tofacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-02-16
    Completion
    2023-05-30
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionTLL-018; TLL-018; TLL-018; Tofacitinib
    PhasePhase 2
    Registry statusCompleted

  • Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management

    NCT04925973 · start 2021-06-01

    Registered record
    Registry ID
    NCT04925973
    Conditions
    Ulcerative Colitis Acute
    Interventions
    Tofacitinib 10 MG [Xeljanz]
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-06-01
    Completion
    2023-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcerative Colitis Acute
    InterventionTofacitinib 10 MG [Xeljanz]
    PhasePhase 2
    Registry statusActive not recruiting

  • Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.

    NCT04721821 · start 2021-01-22

    Registered record
    Registry ID
    NCT04721821
    Conditions
    Arthritis Rheumatoid
    Interventions
    Tofacitinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2021-01-22
    Completion
    2021-11-29
    Enrolment
    7,807

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArthritis Rheumatoid
    InterventionTofacitinib
    PhaseNot recorded
    Registry statusCompleted

  • Predictors of Response to Tofacitinib Treatment in Rheumatoid Arthritis Patients

    NCT04079920 · start 2020-09-22

    Registered record
    Registry ID
    NCT04079920
    Conditions
    Rheumatoid Arthritis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-09-22
    Completion
    2023-02-08
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study of JNJ-64251330 in Healthy Participants

    NCT04552197 · start 2020-09-02

    Registered record
    Registry ID
    NCT04552197
    Conditions
    Healthy
    Interventions
    JNJ-64251330; Tofacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-09-02
    Completion
    2020-12-29
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionJNJ-64251330; Tofacitinib
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Tofacitinib in Hospitalized Participants With COVID-19 Pneumonia Who Are Receiving Standard of Care Therapy

    NCT04412252 · start 2020-07-06

    Registered record
    Registry ID
    NCT04412252
    Conditions
    COVID-19
    Interventions
    Tofacitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2020-07-06
    Completion
    2020-10-18
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOVID-19
    InterventionTofacitinib; Placebo
    PhasePhase 2
    Registry statusWithdrawn

  • Korea Post-marketing Surveillance for Xeljanz (Registered) in Ulcerative Colitis Patients

    NCT04071405 · start 2020-05-12

    Registered record
    Registry ID
    NCT04071405
    Conditions
    Ulcerative Colitis
    Interventions
    Non-intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-05-12
    Completion
    2022-09-26
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcerative Colitis
    InterventionNon-intervention
    PhaseNot recorded
    Registry statusCompleted

  • TOFAcitinib in SARS-CoV2 Pneumonia

    NCT04332042 · start 2020-04-10

    Registered record
    Registry ID
    NCT04332042
    Conditions
    SARS-COv2 Related Interstitial Pneumonia
    Interventions
    Tofacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-04-10
    Completion
    2020-07-10
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSARS-COv2 Related Interstitial Pneumonia
    InterventionTofacitinib
    PhasePhase 2
    Registry statusUnknown

  • Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

    NCT03970837 · start 2019-06-05

    Registered record
    Registry ID
    NCT03970837
    Conditions
    Arthritis, Rheumatoid
    Interventions
    GSK3196165 (Otilimab); Tofacitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2019-06-05
    Completion
    2023-01-18
    Enrolment
    1,764

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArthritis, Rheumatoid
    InterventionGSK3196165 (Otilimab); Tofacitinib; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Tofacitinib for Inflammatory Eye Disease

    NCT03580343 · start 2019-04-04

    Registered record
    Registry ID
    NCT03580343
    Conditions
    Uveitis; Scleritis
    Interventions
    tofacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-04-04
    Completion
    2021-04-04
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUveitis; Scleritis
    Interventiontofacitinib
    PhasePhase 2
    Registry statusUnknown

  • IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis

    NCT03981900 · start 2019-01-04

    Registered record
    Registry ID
    NCT03981900
    Conditions
    Arthritis, Rheumatoid
    Interventions
    Tofacitinib; Tofacitinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-01-04
    Completion
    2023-02-06
    Enrolment
    314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArthritis, Rheumatoid
    InterventionTofacitinib; Tofacitinib
    PhaseNot recorded
    Registry statusCompleted

  • Identify Predictors That Distinguish Between Tofacitinib Responders and Non-responders Based on Genotype and Cellular and Molecular Profiles From Pinch Biopsies, Blood and Stool Samples

    NCT03663400 · start 2018-12-04

    Registered record
    Registry ID
    NCT03663400
    Conditions
    Ulcerative Colitis
    Interventions
    GWAS analysis by Illumina BeadChip
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-12-04
    Completion
    2022-03-24
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUlcerative Colitis
    InterventionGWAS analysis by Illumina BeadChip
    PhaseNot recorded
    Registry statusCompleted

  • PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release Formulation

    NCT04403776 · start 2018-12-03

    Registered record
    Registry ID
    NCT04403776
    Conditions
    Healthy
    Interventions
    tofacitinib MR 11 mg; tofacitinib IR 5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-12-03
    Completion
    2019-02-12
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventiontofacitinib MR 11 mg; tofacitinib IR 5 mg
    PhasePhase 1
    Registry statusCompleted